Glynn Wilson is interviewed by Corporate Road Show to discuss the companie's clinical program on HER2/neu breast cancer, collaborations in cancer and infectious disease, and the progress in the development of a novel expression vector platform. http://lnkd.in/3WKSkK

Follow TapImmune on LinkedIn http://www.linkedin.com/company/tapimmune-inc

Dr. Keith Knutson our key collaborator and discoverer of the HER2/neu antigen technology being developed by TapImmune is interviewed by Corporate Road Show. This interview coincides with his new appointment as Research Program Director in Oncology at the Vaccine and Gene Therapy Institute of Florida . He retains an appointment at the Mayo Clinic, Rochester, MN. http://lnkd.in/xs2zYV

Follow TapImmune on LinkedIn http://www.linkedin.com/company/tapimmune-inc